Mesoblast Limited (NASDAQ:MESO) Sees Large Increase in Short Interest

Mesoblast Limited (NASDAQ:MESO) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 1,010,000 shares, a growth of 20.5% from the August 31st total of 838,200 shares. Based on an average trading volume of 157,200 shares, the short-interest ratio is currently 6.4 days.

Mesoblast Stock Up 7.5 %

Shares of NASDAQ MESO traded up $0.57 during trading on Monday, reaching $8.17. 440,208 shares of the stock were exchanged, compared to its average volume of 867,394. The business’s 50-day moving average price is $6.61 and its 200 day moving average price is $6.53. Mesoblast has a twelve month low of $1.61 and a twelve month high of $8.66. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $932.83 million, a price-to-earnings ratio of -7.29 and a beta of 3.47.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after purchasing an additional 1,663 shares in the last quarter. Chapin Davis Inc. increased its stake in shares of Mesoblast by 50.0% in the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after buying an additional 5,000 shares during the last quarter. Rathbones Group PLC bought a new stake in shares of Mesoblast in the second quarter worth $95,000. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Mesoblast in the second quarter worth $80,000. Finally, Marshall Wace LLP bought a new stake in shares of Mesoblast in the second quarter worth $562,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MESO. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a research report on Thursday, August 29th. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Piper Sandler raised shares of Mesoblast from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $4.00 to $11.00 in a research report on Tuesday, July 23rd. Finally, Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Mesoblast presently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.